{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:56:57Z","timestamp":1792717017174,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41591-021-01301-0","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T12:07:17Z","timestamp":1618229237000},"page":"591-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":382,"title":["Vaccine development for emerging infectious diseases"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-5101","authenticated-orcid":false,"given":"Jean-Louis","family":"Excler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Berkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-6438","authenticated-orcid":false,"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"1301_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1301_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"1301_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061\u20131069 (2020).","journal-title":"JAMA"},{"key":"1301_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17441692.2020.1828982","volume":"16","author":"A Friedler","year":"2021","unstructured":"Friedler, A. Sociocultural, behavioural and political factors shaping the COVID-19 pandemic: the need for a biocultural approach to understanding pandemics and (re)emerging pathogens. Glob. Public Health 16, 17\u201335 (2021).","journal-title":"Glob. Public Health"},{"key":"1301_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0840470420901532","volume":"33","author":"PR Gully","year":"2020","unstructured":"Gully, P. R. Pandemics, regional outbreaks, and sudden-onset disasters. Healthc. Manage. Forum 33, 164\u2013169 (2020).","journal-title":"Healthc. Manage. Forum"},{"key":"1301_CR6","doi-asserted-by":"publisher","first-page":"e1003467","DOI":"10.1371\/journal.ppat.1003467","volume":"9","author":"DM Morens","year":"2013","unstructured":"Morens, D. M. & Fauci, A. S. Emerging infectious diseases: threats to human health and global stability. PLoS Pathog. 9, e1003467 (2013).","journal-title":"PLoS Pathog."},{"key":"1301_CR7","doi-asserted-by":"publisher","first-page":"253ps210","DOI":"10.1126\/scitranslmed.3009872","volume":"6","author":"HD Marston","year":"2014","unstructured":"Marston, H. D., Folkers, G. K., Morens, D. M. & Fauci, A. S. Emerging viral diseases: confronting threats with new technologies. Sci. Transl. Med. 6, 253ps210 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1301_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","volume":"182","author":"DM Morens","year":"2020","unstructured":"Morens, D. M. & Fauci, A. S. Emerging pandemic diseases: how we got to COVID-19. Cell 182, 1077\u20131092 (2020).","journal-title":"Cell"},{"key":"1301_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMp2002106","volume":"382","author":"DM Morens","year":"2020","unstructured":"Morens, D. M., Daszak, P. & Taubenberger, J. K. Escaping Pandora\u2019s box\u2014another novel coronavirus. N. Engl. J. Med. 382, 1293\u20131295 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1301_CR10","first-page":"399","volume":"4","author":"L Sacchetto","year":"2020","unstructured":"Sacchetto, L., Drumond, B. P., Han, B. A., Nogueira, M. L. & Vasilakis, N. Re-emergence of yellow fever in the neotropics\u2014quo vadis? Emerg. Top. Life Sci. 4, 399\u2013410 (2020).","journal-title":"Emerg. Top. Life Sci."},{"key":"1301_CR11","unstructured":"World Health Organization. Yellow fever. https:\/\/www.who.int\/biologicals\/vaccines\/yellow_fever\/en\/ (2015)."},{"key":"1301_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(20)32520-4","volume":"397","author":"A Juan-Giner","year":"2021","unstructured":"Juan-Giner, A. et al. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet 397, 119\u2013127 (2021).","journal-title":"Lancet"},{"key":"1301_CR13","first-page":"178","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara, E., Ketloy, C., Thomas, S. J. & Ruxrungtham, K. Dengue vaccine: global development update. Asian Pac. J. Allergy Immunol. 38, 178\u2013185 (2020).","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"1301_CR14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","volume":"15","author":"SJ Thomas","year":"2019","unstructured":"Thomas, S. J. & Yoon, I. K. A review of Dengvaxia\u00ae: development to deployment. Hum. Vaccin. Immunother. 15, 2295\u20132314 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1301_CR15","doi-asserted-by":"publisher","first-page":"E7730","DOI":"10.1073\/pnas.1608732113","volume":"113","author":"D Hu","year":"2016","unstructured":"Hu, D. et al. Origins of the current seventh cholera pandemic. Proc. Natl Acad. Sci. USA 113, E7730\u2013E7739 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1301_CR16","doi-asserted-by":"publisher","first-page":"A118","DOI":"10.1016\/j.vaccine.2019.12.011","volume":"38","author":"H Shaikh","year":"2020","unstructured":"Shaikh, H., Lynch, J., Kim, J. & Excler, J. L. Current and future cholera vaccines. Vaccine 38, A118\u2013A126 (2020).","journal-title":"Vaccine"},{"key":"1301_CR17","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/mBio.00105-18","volume":"9","author":"EJ Klemm","year":"2018","unstructured":"Klemm, E. J. et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio 9, e00105\u201318 (2018).","journal-title":"mBio"},{"key":"1301_CR18","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciy877","volume":"68","author":"MT Yousafzai","year":"2019","unstructured":"Yousafzai, M. T. et al. Ceftriaxone-resistant Salmonella Typhi outbreak in Hyderabad City of Sindh, Pakistan: high time for the introduction of typhoid conjugate vaccine. Clin. Infect. Dis. 68, S16\u2013S21 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1301_CR19","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.1093\/cid\/ciaa1323","volume":"71","author":"FN Qamar","year":"2020","unstructured":"Qamar, F. N. et al. Antimicrobial resistance in typhoidal salmonella: surveillance for enteric fever in Asia project, 2016\u20132019. Clin. Infect. Dis. 71, S276\u2013S284 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1301_CR20","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.4269\/ajtmh.20-0258","volume":"103","author":"CS Marchello","year":"2020","unstructured":"Marchello, C. S., Carr, S. D. & Crump, J. A. A systematic review on antimicrobial resistance among Salmonella Typhi worldwide. Am. J. Trop. Med. Hyg. 103, 2518\u20132527 (2020).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1301_CR21","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(18)30350-5","volume":"19","author":"JR Andrews","year":"2019","unstructured":"Andrews, J. R. et al. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. Lancet Infect. Dis. 19, e26\u2013e30 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1301_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/QAD.0b013e3283379712","volume":"24","author":"MP D\u2019Souza","year":"2010","unstructured":"D\u2019Souza, M. P. & Frahm, N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 24, 803\u2013809 (2010).","journal-title":"AIDS"},{"key":"1301_CR23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1177\/135965350701200702","volume":"12","author":"JT Lin","year":"2007","unstructured":"Lin, J. T. et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 12, 1107\u20131113 (2007).","journal-title":"Antivir. Ther."},{"key":"1301_CR24","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","volume":"26","author":"JE Martin","year":"2008","unstructured":"Martin, J. E. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26, 6338\u20136343 (2008).","journal-title":"Vaccine"},{"key":"1301_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","volume":"6","author":"ST Jacob","year":"2020","unstructured":"Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Primers 6, 13 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1301_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0204-7","volume":"5","author":"J Wolf","year":"2020","unstructured":"Wolf, J. et al. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. NPJ Vaccines 5, 51 (2020).","journal-title":"NPJ Vaccines"},{"key":"1301_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/d41586-020-03626-1","volume":"589","author":"P Ball","year":"2021","unstructured":"Ball, P. The lightning-fast quest for COVID vaccines\u2014and what it means for other diseases. Nature 589, 16\u201318 (2021).","journal-title":"Nature"},{"key":"1301_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev-micro-090817-062414","volume":"72","author":"H Feldmann","year":"2018","unstructured":"Feldmann, H., Feldmann, F. & Marzi, A. Ebola: lessons on vaccine development. Annu. Rev. Microbiol. 72, 423\u2013446 (2018).","journal-title":"Annu. Rev. Microbiol."},{"key":"1301_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/epirev\/mxz012","volume":"41","author":"D Gouglas","year":"2019","unstructured":"Gouglas, D., Christodoulou, M., Plotkin, S. A. & Hatchett, R. CEPI: driving progress toward epidemic preparedness and response. Epidemiol. Rev. 41, 28\u201333 (2019).","journal-title":"Epidemiol. Rev."},{"key":"1301_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMp1613577","volume":"376","author":"JA Rottingen","year":"2017","unstructured":"Rottingen, J. A. et al. New vaccines against epidemic infectious diseases. N. Engl. J. Med. 376, 610\u2013613 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1301_CR31","doi-asserted-by":"publisher","first-page":"608460","DOI":"10.3389\/fimmu.2020.608460","volume":"11","author":"JB Sandbrink","year":"2020","unstructured":"Sandbrink, J. B. & Shattock, R. J. RNA vaccines: a suitable platform for tackling emerging pandemics? Front. Immunol. 11, 608460 (2020).","journal-title":"Front. Immunol."},{"key":"1301_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).","journal-title":"NPJ Vaccines"},{"key":"1301_CR33","unstructured":"US Department of Health and Human Health Services. Explaining Operation Warp Speed. https:\/\/health.mo.gov\/living\/healthcondiseases\/communicable\/novel-coronavirus-lpha\/pdf\/fact-sheet-operation-warp-speed.pdf 2020)."},{"key":"1301_CR34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","volume":"19","author":"D van Riel","year":"2020","unstructured":"van Riel, D. & de Wit, E. Next-generation vaccine platforms for COVID-19. Nat. Mater. 19, 810\u2013812 (2020).","journal-title":"Nat. Mater."},{"key":"1301_CR35","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1301_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1301_CR37","unstructured":"US Food and Drug Administration. FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 (2020)."},{"key":"1301_CR38","unstructured":"US Food and Drug Administration. FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid (2020)."},{"key":"1301_CR39","unstructured":"European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-first-covid-19-vaccine-authorisation-eu (2020)."},{"key":"1301_CR40","unstructured":"European Medicines Agency. EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-covid-19-vaccine-moderna-authorisation-eu (2021)."},{"key":"1301_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/vaccines7020037","volume":"7","author":"MA Liu","year":"2019","unstructured":"Liu, M. A. A Comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines 7, 37 (2019).","journal-title":"Vaccines"},{"key":"1301_CR42","doi-asserted-by":"publisher","unstructured":"Pollard, A. J. et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(20)30476-X (2020).","DOI":"10.1016\/S1473-3099(20)30476-X"},{"key":"1301_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hs.2019.0148","volume":"18","author":"AA Adalja","year":"2020","unstructured":"Adalja, A. A., Watson, M., Cicero, A. & Inglesby, T. Vaccine platform technologies: a potent tool for emerging infectious disease vaccine development. Health Secur. 18, 59\u201360 (2020).","journal-title":"Health Secur."},{"key":"1301_CR44","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","volume":"18","author":"JL Excler","year":"2019","unstructured":"Excler, J. L. & Kim, J. H. Novel prime-boost vaccine strategies against HIV-1. Expert Rev. Vaccines 18, 765\u2013779 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"1301_CR45","unstructured":"European Pharmaceutical Review. AstraZeneca to test combination of AZD1222 and Sputnik V vaccines. https:\/\/www.europeanpharmaceuticalreview.com\/news\/136683\/astrazeneca-to-test-combination-of-azd1222-and-sputnik-v-vaccines\/ (2020)."},{"key":"1301_CR46","unstructured":"World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (2021)."},{"key":"1301_CR47","first-page":"181","volume":"95","author":"B Fritzell","year":"1998","unstructured":"Fritzell, B. Bridging studies. Dev. Biol. Stand. 95, 181\u2013188 (1998).","journal-title":"Dev. Biol. Stand."},{"key":"1301_CR48","doi-asserted-by":"crossref","unstructured":"WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation. Placebo-controlled trials of Covid-19 vaccines\u2014why we still need them. N. Engl. J. Med. 384, e2 (2021).","DOI":"10.1056\/NEJMp2033538"},{"key":"1301_CR49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.1996.03530290060038","volume":"275","author":"J Clemens","year":"1996","unstructured":"Clemens, J., Brenner, R., Rao, M., Tafari, N. & Lowe, C. Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA 275, 390\u2013397 (1996).","journal-title":"JAMA"},{"key":"1301_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","volume":"27","author":"JH Kim","year":"2021","unstructured":"Kim, J. H., Marks, F. & Clemens, J. D. Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med. 27, 205\u2013211 (2021).","journal-title":"Nat. Med."},{"key":"1301_CR51","unstructured":"Follmann, D. et al. Assessing durability of vaccine effect following blinded crossover in COVID-19 vaccine efficacy trials. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.12.14.20248137v1 (2020)."},{"key":"1301_CR52","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety, 27\u201328 May 2020. https:\/\/www.who.int\/vaccine_safety\/committee\/reports\/May_2020\/en\/ (2020)."},{"key":"1301_CR53","unstructured":"World Health Organization. COVID-19 vaccines: safety surveillance manual. https:\/\/apps.who.int\/iris\/handle\/10665\/338400 (2020)."},{"key":"1301_CR54","unstructured":"European Medicines Agency. Pharmacovigilance plan of the EU Regulatory Network for COVID-19 Vaccines. https:\/\/www.ema.europa.eu\/en\/documents\/other\/pharmacovigilance-plan-eu-regulatory-network-covid-19-vaccines_en.pdf (2020)."},{"key":"1301_CR55","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/jama.2020.19692","volume":"324","author":"GM Lee","year":"2020","unstructured":"Lee, G. M., Romero, J. R. & Bell, B. P. Postapproval vaccine safety surveillance for COVID-19 vaccines in the US. JAMA 324, 1937\u20131938 (2020).","journal-title":"JAMA"},{"key":"1301_CR56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/14760584.2016.1188695","volume":"15","author":"MP Kieny","year":"2016","unstructured":"Kieny, M. P. & Rago, L. Regulatory policy for research and development of vaccines for public health emergencies. Expert Rev. Vaccines 15, 1075\u20131077 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"1301_CR57","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1016\/j.vaccine.2020.05.064","volume":"38","author":"PH Lambert","year":"2020","unstructured":"Lambert, P. H. et al. Consensus summary report for CEPI\/BC March 12\u201313, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine 38, 4783\u20134791 (2020).","journal-title":"Vaccine"},{"key":"1301_CR58","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14760584.2020.1800463","volume":"19","author":"RM Zellweger","year":"2020","unstructured":"Zellweger, R. M., Wartel, T. A., Marks, F., Song, M. & Kim, J. H. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns. Expert Rev. Vaccines 19, 691\u2013698 (2020).","journal-title":"Expert Rev. Vaccines"},{"key":"1301_CR59","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/AOG.0b013e3181d57947","volume":"115","author":"AA Creanga","year":"2010","unstructured":"Creanga, A. A. et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet. Gynecol. 115, 717\u2013726 (2010).","journal-title":"Obstet. Gynecol."},{"key":"1301_CR60","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S2214-109X(15)70009-4","volume":"3","author":"C Menendez","year":"2015","unstructured":"Menendez, C., Lucas, A., Munguambe, K. & Langer, A. Ebola crisis: the unequal impact on women and children\u2019s health. Lancet Glob. Health 3, e130 (2015).","journal-title":"Lancet Glob. Health"},{"key":"1301_CR61","unstructured":"The PREVENT Working Group. Pregnant women and vaccines against emerging epidemic threats: ethics guidance on preparedness, research and response. http:\/\/vax.pregnancyethics.org\/prevent-guidance (2018)."},{"key":"1301_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.vaccine.2019.01.011","volume":"39","author":"CB Krubiner","year":"2021","unstructured":"Krubiner, C. B. et al. Pregnant women and vaccines against emerging epidemic threats: ethics guidance for preparedness, research, and response. Vaccine 39, 85\u2013120 (2021).","journal-title":"Vaccine"},{"key":"1301_CR63","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","volume":"26","author":"AWD Edridge","year":"2020","unstructured":"Edridge, A. W. D. et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med. 26, 1691\u20131693 (2020).","journal-title":"Nat. Med."},{"key":"1301_CR64","doi-asserted-by":"publisher","unstructured":"Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature https:\/\/doi.org\/10.1038\/s41586-020-2895-3 (2020).","DOI":"10.1038\/s41586-020-2895-3"},{"key":"1301_CR65","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827 (2020).","journal-title":"Cell"},{"key":"1301_CR66","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1126\/science.abe8499","volume":"370","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464\u20131468 (2020).","journal-title":"Science"},{"key":"1301_CR67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cell.2020.11.020","volume":"184","author":"E Volz","year":"2021","unstructured":"Volz, E. et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 184, 64\u201375.e11 (2021).","journal-title":"Cell"},{"key":"1301_CR68","unstructured":"Faria, N. R. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological https:\/\/virological.org\/t\/586 (2020)."},{"key":"1301_CR69","doi-asserted-by":"publisher","unstructured":"Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.01.18.427166 (2021).","DOI":"10.1101\/2021.01.18.427166"},{"key":"1301_CR70","unstructured":"BBC. Covid: South Africa halts AstraZeneca vaccine rollout over new variant. https:\/\/www.bbc.com\/news\/world-africa-55975052 (2021)."},{"key":"1301_CR71","doi-asserted-by":"publisher","first-page":"n296","DOI":"10.1136\/bmj.n296","volume":"372","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 372, n296 (2021).","journal-title":"BMJ"},{"key":"1301_CR72","unstructured":"Johnson & Johnson. Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial. https:\/\/www.jnj.com\/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial (2021)."},{"key":"1301_CR73","unstructured":"World Health Organization. Global Influenza Surveillance and Response System (GISRS). https:\/\/www.who.int\/influenza\/gisrs_laboratory\/en\/"},{"key":"1301_CR74","unstructured":"US Food and Drug Administration. Emergency use authorization. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization (2021)."},{"key":"1301_CR75","unstructured":"European Medicines Agency. Conditional marketing authorization. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/conditional-marketing-authorisation (2020)."},{"key":"1301_CR76","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0140-6736(20)32337-0","volume":"396","author":"MJ Smith","year":"2020","unstructured":"Smith, M. J., Ujewe, S., Katz, R. & Upshur, R. E. G. Emergency use authorisation for COVID-19 vaccines: lessons from Ebola. Lancet 396, 1707\u20131709 (2020).","journal-title":"Lancet"},{"key":"1301_CR77","unstructured":"World Health Organization. Emergency use listing procedure. https:\/\/www.who.int\/publications\/m\/item\/emergency-use-listing-procedure (2020)."},{"key":"1301_CR78","unstructured":"Pharmaceutical Technology. Russia approves Sputnik V Covid-19 vaccine for senior citizens. https:\/\/www.pharmaceutical-technology.com\/news\/russia-sputnik-senior-citizens\/ (2021)."},{"key":"1301_CR79","doi-asserted-by":"publisher","unstructured":"Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(21)00234-8 (2021).","DOI":"10.1016\/S0140-6736(21)00234-8"},{"key":"1301_CR80","unstructured":"Xinhuanet. China approves first self-developed COVID-19 vaccine. http:\/\/www.xinhuanet.com\/english\/2020-12\/31\/c_139632402.htm (2020)."},{"key":"1301_CR81","unstructured":"Sinopharm. China grants conditional market approval for Sinopharm CNBG\u2019s COVID-19 vaccine. http:\/\/www.sinopharm.com\/en\/s\/1395-4173-38862.html (2021)."},{"key":"1301_CR82","unstructured":"CNBC. Dubai is offering the Pfizer vaccine to residents for free in addition to China\u2019s Sinopharm shot. https:\/\/www.cnbc.com\/2020\/12\/23\/dubai-offering-pfizer-sinopharm-covid-vaccines-to-residents-for-free.html (2020)."},{"key":"1301_CR83","unstructured":"Reuters. China approves Sinovac Biotech COVID-19 vaccine for general public use. https:\/\/www.reuters.com\/article\/us-health-coronavirus-vaccine-sinovac-idUSKBN2A60AY (2021)."},{"key":"1301_CR84","unstructured":"Reuters. Pakistan approves Chinese CanSinoBIO COVID vaccine for emergency use. https:\/\/www.reuters.com\/article\/us-health-coronavirus-pakistan-vaccine\/pakistan-approves-chinese-cansinobio-covid-vaccine-for-emergency-use-idUSKBN2AC1FG (2021)."},{"key":"1301_CR85","unstructured":"Euronews. Coronavirus: 15m people in the UK have now had their first COVID jab\u2014what about wider Europe? https:\/\/www.euronews.com\/2021\/02\/14\/coronavirus-15m-people-in-the-uk-have-now-had-their-first-covid-jab-what-about-wider-europ (2021)."},{"key":"1301_CR86","unstructured":"Deng, C. & Malsin, J. China\u2019s Covid-19 vaccine makers struggle to meet demand. The Wall Street Journal https:\/\/www.wsj.com\/articles\/chinas-covid-19-vaccine-makers-struggle-to-meet-demand-11612958560 (10 February 2021)."},{"key":"1301_CR87","doi-asserted-by":"publisher","first-page":"B176","DOI":"10.1016\/j.vaccine.2012.11.060","volume":"31","author":"S Pagliusi","year":"2013","unstructured":"Pagliusi, S. et al. Developing countries vaccine manufacturers network: doing good by making high-quality vaccines affordable for all. Vaccine 31, B176\u2013B183 (2013).","journal-title":"Vaccine"},{"key":"1301_CR88","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/1469-0691.12568","volume":"20","author":"S Jadhav","year":"2014","unstructured":"Jadhav, S., Gautam, M. & Gairola, S. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices. Clin. Microbiol. Infect. 20, 37\u201344 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"1301_CR89","doi-asserted-by":"publisher","first-page":"e20201288","DOI":"10.1084\/jem.20201288","volume":"217","author":"JH Kim","year":"2020","unstructured":"Kim, J. H. SARS-CoV-2 vaccine development, access, and equity. J. Exp. Med. 217, e20201288 (2020).","journal-title":"J. Exp. Med."},{"key":"1301_CR90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/17441692.2020.1860249","volume":"16","author":"G Nhamo","year":"2020","unstructured":"Nhamo, G., Chikodzi, D., Kunene, H. P. & Mashula, N. COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs. Glob. Public Health 16, 319\u2013339 (2020).","journal-title":"Glob. Public Health"},{"key":"1301_CR91","unstructured":"World Bank. Global economy to expand by 4% in 2021; vaccine deployment and investment key to sustaining the recovery. https:\/\/www.worldbank.org\/en\/news\/press-release\/2021\/01\/05\/global-economy-to-expand-by-4-percent-in-2021-vaccine-deployment-and-investment-key-to-sustaining-the-recovery (2021)."},{"key":"1301_CR92","unstructured":"UN News. WHO chief warns against \u2018catastrophic moral failure\u2019 in COVID-19 vaccine access. https:\/\/news.un.org\/en\/story\/2021\/01\/1082362 (18 January 2021)."},{"key":"1301_CR93","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1126\/science.aba9757","volume":"368","author":"M Chinazzi","year":"2020","unstructured":"Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science 368, 395\u2013400 (2020).","journal-title":"Science"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01301-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T19:02:54Z","timestamp":1764183774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01301-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.-L.E. is a consultant for vaccine safety for the Brighton Collaboration, Johnson & Johnson and the US Military HIV Research Program. J.H.K. is a consultant to SK Bioscience. M.S. has a financial interest in Sanofi (shares). S.B. does not have any financial or nonfinancial conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}